We are working to repurpose our novel monoclonal antibody Itolizumab (used in psoriasis) to treat complications caused by Covid-19 infection. If we can successfully establish the potential role for our molecule in treating Covid-19 complications, it will enable us to address a critical unmet need, Kiran Mazumdar-Shaw said.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ylSBGp
via IFTTT
0 comments:
Post a Comment